Free Trial
NASDAQ:ALDX

Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis

Aldeyra Therapeutics logo
$5.26
-0.08 (-1.50%)
(As of 10/31/2024 ET)

About Aldeyra Therapeutics Stock (NASDAQ:ALDX)

Key Stats

Today's Range
$5.16
$5.34
50-Day Range
$5.22
$6.32
52-Week Range
$1.53
$6.55
Volume
334,760 shs
Average Volume
490,493 shs
Market Capitalization
$312.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Aldeyra Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
33rd Percentile Overall Score

ALDX MarketRank™: 

Aldeyra Therapeutics scored higher than 33% of companies evaluated by MarketBeat, and ranked 825th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aldeyra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aldeyra Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Aldeyra Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Aldeyra Therapeutics are expected to decrease in the coming year, from ($0.51) to ($0.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aldeyra Therapeutics is -10.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aldeyra Therapeutics is -10.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aldeyra Therapeutics has a P/B Ratio of 2.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Aldeyra Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    5.92% of the float of Aldeyra Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aldeyra Therapeutics has a short interest ratio ("days to cover") of 6.4.
  • Change versus previous month

    Short interest in Aldeyra Therapeutics has recently increased by 13.33%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Aldeyra Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Aldeyra Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.92% of the float of Aldeyra Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aldeyra Therapeutics has a short interest ratio ("days to cover") of 6.4.
  • Change versus previous month

    Short interest in Aldeyra Therapeutics has recently increased by 13.33%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Aldeyra Therapeutics has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Aldeyra Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 4 people have searched for ALDX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aldeyra Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.50% of the stock of Aldeyra Therapeutics is held by insiders.

  • Percentage Held by Institutions

    59.71% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Aldeyra Therapeutics' insider trading history.
Receive ALDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALDX Stock News Headlines

Unveiled: NVIDIA’s "Secret Royalty" Program
Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?
Aldeyra Therapeutics extends loan agreement terms
See More Headlines

ALDX Stock Analysis - Frequently Asked Questions

Aldeyra Therapeutics' stock was trading at $3.51 at the beginning of the year. Since then, ALDX shares have increased by 51.0% and is now trading at $5.30.
View the best growth stocks for 2024 here
.

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) released its quarterly earnings data on Wednesday, October, 27th. The biotechnology company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.01.

Aldeyra Therapeutics' top institutional shareholders include PFG Investments LLC (0.65%), International Assets Investment Management LLC (0.48%), SG Americas Securities LLC (0.03%) and US Bancorp DE (0.01%). Insiders that own company stock include Perceptive Advisors Llc, Todd C Brady, Bruce Greenberg, Martin Joseph Joyce and Nancy Miller-Rich.
View institutional ownership trends
.

Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aldeyra Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Viking Therapeutics (VKTX), Alibaba Group (BABA) and Netflix (NFLX).

Company Calendar

Last Earnings
10/27/2021
Today
10/31/2024
Next Earnings (Estimated)
11/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALDX
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+90.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-37,540,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.04 per share

Miscellaneous

Free Float
54,371,000
Market Cap
$312.52 million
Optionable
Optionable
Beta
1.44

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NASDAQ:ALDX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners